Home / Intelligence / Case Studies / Strategic Recommendations About Potential Actions to Shape Bone Health Policy
Trinity completed a detailed analogue assessment to understand how various stakeholders are involved in shaping health policies across markets.
Geographic Scope: 
Client Situation
The client wanted to identify best practices as well as the external stakeholders they should consider working with to efficiently shape global bone health policy.
Trinity’s Solution
Trinity conducted a systematic analogue disease area filtration to understand the disease areas where health policy development is most comparable to the bone health space.
Trinity then conducted exhaustive secondary research within each analogue disease area to understand the most relevant health policy shaping stakeholders, their actions, and consequent impact; leverage key learnings from each analogue disease area to inform bone health policy recommendations.
Deliverables
- Analogue selection and methodology
- High level executive summary explaining overall trends
- Analogue assessments for five disease areas of interest
- Recommendations for exploring partnerships in developing bone health policy
Project Outcomes & Impact
The client was able to understand the strategic actions they could take in order to shape bone health policy across several markets and define the success factors that drive stakeholder engagement in policy-shaping activities. The client was also able to develop compelling case studies in order to gather cross-functional buy-in.
Related Intelligence
Briefs
Unlocking Environmental Sustainability Opportunities in the Life Sciences
The healthcare industry has long been known for its significant environmental impact, including contributing ~5% of total global emissions. As awareness of this impact has increased, life sciences companies are now actively committing to climate resilience and environmental sustainability through various initiatives, including net-zero commitments. Trinity Life Sciences has identified several recent trends driving this […]
Read More
Briefs
Global Dossiers in the Joint Clinical Assessment Era: Impacts and Implications
Joint clinical assessment (JCA) is a European Union (EU) initiative intended to improve patient access to health technologies in Europe through a harmonized clinical health technology assessment (HTA) process. From January 2025, all new oncology medicines and advanced therapy medicinal products will go through the JCA process, followed by all orphan medicinal products from 2028 […]
Read More
Briefs
Assessing the Influence of ICER Reports on U.S. Payer Decision Making
The Institute for Clinical and Economic Review (ICER) is an independent, non-profit research organization dedicated to assessing the value of healthcare interventions, including diagnostics, devices, digital therapeutics and prescription drugs. Although ICER’s assessments do not represent a mandate for product funding or pricing in the U.S. in the same way as, for example, National Institute […]
Read More